Antidepressants are among the most prescribed and most misunderstood drugs in medicine. The old explanation — “they correct a chemical imbalance” — turns out to have been an oversimplification that the science has substantially moved beyond, leaving patients confused about what the pills actually do. How do antidepressants really work, and is now a good time to understand them (perhaps because you or someone you love is considering them)? This guide explains the current science honestly: what the drugs do in the brain, why the chemical-imbalance story was retired, how long they take, what the side effects really are, and how to think about the decision.

You will learn the neuroscience of depression and antidepressant action, the main drug classes, realistic timelines and what to expect, the side-effect profile honestly presented, and how the decision to start (or stop) should be made.

What depression is (beyond “low serotonin”)

The “chemical imbalance” theory — depression as a simple serotonin deficiency corrected by SSRIs — was always a marketing simplification of a tentative hypothesis, and recent comprehensive reviews found no consistent evidence that depression is caused by low serotonin. This does not mean antidepressants do not work; it means the explanation was wrong. The current understanding: depression involves disrupted neural circuits (particularly in mood, reward, and stress-regulation networks), impaired neuroplasticity (the brain’s ability to adapt and rewire), chronic stress effects on the hippocampus and prefrontal cortex, inflammatory processes in some patients, and genetic vulnerability interacting with life events. It is a systems disorder, not a single-chemical deficit — which is why no single drug works for everyone and why the drugs’ effects are more subtle and interesting than “topping up serotonin”. If low mood is affecting daily life, non-medication approaches to low mood are worth understanding alongside — treatment works best as a package.

How antidepressants actually work (current science)

Most antidepressants increase the availability of monoamine neurotransmitters (serotonin, norepinephrine, dopamine) in the synaptic gap — SSRIs block serotonin’s reuptake, SNRIs block serotonin and norepinephrine reuptake, and so on. But here is the key puzzle the old theory could not explain: this chemical change happens within hours, yet mood improvement takes weeks. The resolution: the immediate chemical change triggers slower downstream adaptations — increased BDNF (brain-derived neurotrophic factor, essentially fertiliser for neurons), growth of new neural connections, reversal of stress-induced hippocampal shrinkage, and gradual normalisation of the overactive stress circuits. In other words, the drugs do not “fix a deficiency” — they promote neuroplasticity, giving the brain the biological conditions to rewire out of the depressed state, particularly combined with the new experiences and behaviours that therapy and life changes provide. This is why antidepressants plus therapy consistently outperform either alone: the drug creates the plasticity, the therapy guides the rewiring. The NICE guidelines on depression reflect this combined-treatment evidence.

The main classes (what is prescribed in the UK)

SSRIs (sertraline, fluoxetine, citalopram, escitalopram): first-line in the UK — effective, well-studied, and generally the best-tolerated. Sertraline is the most commonly prescribed. SNRIs (venlafaxine, duloxetine): second-line or for depression with significant anxiety or pain symptoms; discontinuation can be trickier. Mirtazapine: often chosen when insomnia or appetite loss dominate (it is sedating and appetite-stimulating); useful in older patients. TCAs (amitriptyline): older class, effective but more side effects and dangerous in overdose — now mostly used at low doses for pain and migraine rather than depression. Newer options: vortioxetine, agomelatine (different mechanisms, niche uses). Choice depends on symptom profile, side-effect priorities, interactions, and patient history — there is no universally “best” antidepressant, which is why switching is common and not a failure. Roughly 60–70% of patients respond to the first or second drug tried.

Timelines: what to actually expect

Weeks 1–2: side effects often appear before benefits — nausea, headache, sleep changes, sometimes increased anxiety. This is the hardest period and when most people quit; knowing it is temporary and expected helps enormously. Weeks 2–4: early subtle shifts — sleep or appetite may normalise before mood lifts; some people notice “the volume turning down” on negative rumination. Weeks 4–8: the therapeutic effect typically emerges — this is when efficacy is properly assessed. Weeks 8–12: full effect and dose optimisation. If there is no meaningful improvement by 6–8 weeks on an adequate dose, guidelines recommend switching or augmenting — staying on an ineffective drug for months is the common error. Duration: after a first episode, typically 6–12 months after feeling better (stopping too early is the leading cause of relapse); recurrent depression often warrants longer-term treatment. Improvement is usually gradual, not a sudden lifting — many people realise retrospectively that they have been feeling better for weeks. Keeping a simple mood diary helps track the slow change objectively. Complementary practices like journaling for mental clarity pair well with the process.

Side effects, honestly

Common and usually transient: nausea, headache, dry mouth, sleep disturbance (insomnia or drowsiness depending on the drug), and initial anxiety — mostly resolving in 1–3 weeks. Common and persistent: sexual dysfunction (reduced libido, delayed orgasm — affects a significant minority; the most under-discussed side effect and a leading cause of discontinuation; switching drugs or dose adjustment often helps, so raise it rather than suffering silently), weight changes (variable by drug — mirtazapine tends toward gain, fluoxetine is weight-neutral for most), and emotional blunting (feeling “flattened” — dose-related, worth discussing). Serious but rare: serotonin syndrome (with interactions), hyponatraemia in older patients, and increased suicidal thoughts in young people during initiation — the reason for close monitoring when young patients start. Discontinuation: stopping abruptly can cause withdrawal-like symptoms (dizziness, “brain zaps”, flu-like feelings) — always taper under medical guidance; this is dependence in the pharmacological sense, not addiction, but it demands respect. The honest summary: side effects are real and common, serious harms are rare, and most side effects are manageable through drug choice, dose adjustment, or switching — the conversation with the prescriber is the treatment working as intended.

Making the decision (and stopping well)

The decision to start is individual and should be collaborative: consider severity (mild depression often responds to therapy and lifestyle alone; moderate-to-severe usually warrants medication as part of treatment), functioning (is daily life impaired?), history (previous episodes predict future ones), and preference (your values matter — no one should be coerced). The Royal College of Psychiatrists publishes patient information on antidepressants to support these conversations. Starting well: begin when you can tolerate the 2-week adjustment (not the week before exams or a major deadline if avoidable), arrange follow-up (the prescriber should review at 2, 4, and 8 weeks), and tell someone close what to watch for. Stopping well: never abruptly — taper over weeks to months depending on drug and duration, ideally during a stable period (not mid-crisis), with a relapse plan agreed in advance (warning signs, who to contact, when to restart). Most people who need antidepressants benefit greatly; a minority do not respond to drugs and need other approaches (therapy intensification, newer modalities). Either outcome is data, not failure. For crisis support, the Samaritans (116 123, free, 24/7) and NHS urgent mental health helplines are always available.

Conclusion

Antidepressants work not by correcting a simple chemical imbalance — that story has been retired — but by increasing monoamine availability, which over weeks promotes the neuroplasticity (BDNF, new connections, normalised stress circuits) that lets the brain rewire out of depression, especially combined with therapy. Expect side effects before benefits (weeks 1–2), real improvement by weeks 4–8, and 6–12 months of treatment after recovery for a first episode. Side effects are common but mostly manageable; serious harms are rare; stopping requires tapering. The decision is personal and collaborative — made with a prescriber, informed by the evidence, and revisited honestly. The drugs are tools, not character judgments, and using them well is a skill worth understanding whether you ever need them or love someone who does.

Frequently Asked Questions

How do antidepressants work?

They increase serotonin/norepinephrine availability in the brain, which over weeks promotes neuroplasticity — new neural connections and normalised stress circuits. The chemical change is immediate but mood improvement takes 4–8 weeks because the brain needs time to rewire. They work best combined with therapy.

Is depression caused by a chemical imbalance?

The simple “low serotonin” theory is not supported by current evidence — depression is a systems disorder involving neural circuits, neuroplasticity, stress effects, and inflammation. Antidepressants remain effective; the explanation for why has simply become more sophisticated.

How long do antidepressants take to work?

Side effects appear in weeks 1–2 (before benefits); early shifts in sleep or rumination in weeks 2–4; meaningful mood improvement typically by weeks 4–8. If no improvement by 6–8 weeks on an adequate dose, guidelines recommend switching.

Do antidepressants have serious side effects?

Common side effects (nausea, sleep changes, sexual dysfunction, emotional blunting) are real but mostly manageable through drug choice or dose adjustment. Serious harms are rare. Never stop abruptly — tapering under medical guidance prevents discontinuation symptoms.